Educational Risk Minimisation Materials for Ultomiris (ravulizumab) 300 mg concentrate for solution for infusion

Ravulizumab increases risk of meningococcal infection. These materials aim to remind healthcare professionals about selected prevention measures, detection, careful monitoring and/or proper management of selected safety concerns, as well as making patients aware of risks.

Alexion Pharmaceuticals Ltd